U-92,016-A
|  | |
| Identifiers | |
|---|---|
| IUPAC name 
 | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | 
 | 
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H25N3 | 
| Molar mass | 295.430 g·mol−1 | 
| 3D model (JSmol) | |
| SMILES 
 | |
| InChI 
 | |
| (verify) | |
U-92,016-A is a psychoactive drug and research chemical used in scientific studies. It acts as a potent, high efficacy, and selective 5-HT1A receptor full agonist with a long duration of action.[1][2] It has been suggested that it could be developed as an anxiolytic or antidepressant drug.[1]
References
- 1 2 Romero AG, Leiby JA, McCall RB, Piercey MF, Smith MW, Han F (1993). "Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants". J Med Chem. 36 (15): 2066–2074. doi:10.1021/jm00067a003. PMID 8101876.
- ↑ McCall RB, Romero AG, Bienkowski MJ, Harris DW, McGuire JC, Piercey MF, Shuck ME, Smith MW, Svensson KA, Schreur PJ, et al. (1994). "Characterization of U-92016A as a selective, orally active, high intrinsic activity 5-hydroxytryptamine1A agonist". J Pharmacol Exp Ther. 271 (2): 875–883. PMID 7965808.
| 5-HT1AR agonists | |
|---|---|
| GABAAR PAMs | 
 | 
| Gabapentinoids (α2δ VDCC blockers) | |
| Antidepressants | 
 | 
| Sympatholytics (Antiadrenergics) | 
 | 
| Others | |
| 
 | |
| Serotonin receptor modulators | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5-HT1 | 
 | ||||||||||||||||||||||||||||||||||||||
| 5-HT2 | 
 | ||||||||||||||||||||||||||||||||||||||
| 5-HT3–7 | 
 | ||||||||||||||||||||||||||||||||||||||
| 
 | |||||||||||||||||||||||||||||||||||||||
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

